Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.

Alessandro D SantinIgnace VergoteAntonio González-MartínKathleen MooreAna OakninIgnacio RomeroSami DiabLarry J CopelandBradley J Monk Robert L ColemanThomas J HerzogJonathan SiegelLinda KastenAndreas SchlickerAnke SchulzKarl KöchertAnnette O WalterBarrett H ChildsCem ElbiIurie Bulat

Published in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2022)

NCT02751918.

Keyphrases

cancer therapy
drug delivery
randomized controlled trial
cross sectional
recombinant human